|Printable version||E-mail this to a friend|
Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour
These results – from a clinical trial for patients with anaplastic glioma run by the European Organisation for Research and Treatment of Cancer (EORTC)(link is external) and funded in UK by Cancer Research UK – were presented at the 2016 American Society of Clinical Oncology (ASCO)(link is external) Annual Meeting in Chicago last week*.
The phase III clinical trial compared survival for patients whose tumours were thought to be less likely to respond to chemotherapy because they did not have mutations in two genes called 1p and 19q.
750 patients from institutes around the world were split into four groups and either given:
- Radiotherapy alone
- Radiotherapy at the same time as chemotherapy
- Radiotherapy then chemotherapy
- Radiotherapy at the same time as and followed by chemotherapy.
Giving chemotherapy after radiotherapy (groups three and four) halted tumour growth for 43 months after treatment, compared with 19 months for those who only had radiotherapy (groups one and two).
This improvement resulted in 56 per cent of patients given radiotherapy then chemotherapy surviving for five years, compared with only 44 per cent of those who did not.
While giving chemotherapy after radiotherapy has improved survival and is now standard care for these patients, the benefits of chemotherapy at the same time as radiotherapy are still unclear and need further follow-up.
Around 280 people are diagnosed with anaplastic gliomas each year in England.
UK trial lead Dr Sara Erridge, consultant oncologist at the Edinburgh Cancer Centre, said: “Our important study showed that giving temozolomide chemotherapy after radiotherapy delays progression and significantly improves survival for this group of patients. This trial has changed the way we manage patients with this type of tumour with radiotherapy followed by temozolomide chemotherapy now being the standard of care.”
Martin van den Bent, member of the EORTC Board and study coordinator, said: “This study demonstrates the value of collaborative academic research in improving the standard of care for rare cancers. Through this partnership between EORTC, Cancer Research UK, North American and Australian study groups we were able to involve a large enough group of patients with this rare tumor type, allowing us to draw definitive conclusions that guide future treatment decisions in this disease.”
Cancer Research UK scientists led the development of temozolomide chemotherapy, including its discovery in the lab and the development and first clinical trials of the drug in cancer patients. The treatment is used worldwide to treat glioblastoma – the most common type of adult primary brain tumour.
Dr Ian Walker, Cancer Research UK’s director of clinical research, said: “The data from this trial is an important step forward for patients with anaplastic glioma. Many types of brain cancer are difficult to treat which is why we have committed to investing in more research in these hard-to-treat cancers. It wouldn’t have been possible for our researchers to discover and develop temozolomide without the generous donations of our supporters. And thanks to research like this we hope to be able to increase survival for more patients in the future.”
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Notes to Editor
* More information about the BR14/CATNON trial available here: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-radiotherapy-with-and-without-temozolomide-for-anaplastic-glioma-BR14
Latest News from
Wales Audit Office - Betsi Cadwaladr Health Board moving in the right direction25/06/2017 16:40:00
The Auditor General for Wales and Chief Executive of Healthcare Inspectorate Wales (HIW) have called on Betsi Cadwaladr University Health Board to continue to show “energetic, brave and visible leadership” to build on the progress they have already made to improve services.
IWF (Internet Watch Foundation) channel launch announcement03/04/2017 08:45:00
IWF (Internet Watch Foundation) is the latest stakeholder channel available on the WiredGov service.
SatelLife competition winners announced21/03/2017 11:15:00
Nine young space entrepreneurs have won a share of £50K for innovative ideas on how to use satellite data to improve life on Earth.
Geoplace Stakeholder Channel Launch announcement12/01/2017 12:43:03
We are delighted to be featuring news and insights from GeoPlace as a stakeholder available from the WiredGov channel.
GeoPlace is a world class expert in address and street information management, working to help the public and private sectors’ maximise the value of their spatial information for better decision making.